What is the incidence, typical clinical manifestations, and prognosis of disseminated (miliary) tuberculosis in children?

Incidence, Clinical Manifestations, and Prognosis of Disseminated (Miliary) Tuberculosis in Children

Disseminated tuberculosis in children is relatively common, accounting for approximately 8.3% of all pediatric TB admissions, with the highest risk in children under 5 years of age (particularly infants under 1 year), and carries a mortality rate of 14-30%, which increases significantly to 31.9% when central nervous system involvement is present 1, 2.

Incidence and Epidemiology

Miliary TB represents a substantial burden in the pediatric population:

• Age distribution: The median age at presentation is 10.5 months, with 52% of cases occurring in children younger than 1 year 2. Most cases (all but 3 patients in one series) occur in children below 6 years of age 3.

• Relative frequency: Miliary TB accounts for 8.3% of all tuberculosis admissions in children annually, compared to only 1.3% in adults, confirming this is predominantly a pediatric complication 2.

• BCG vaccination status: Despite vaccination, miliary TB still occurs—88% of children in one series had documented BCG vaccination 2, and cases have been reported even in recently vaccinated infants 4, 5. The absence of a BCG scar despite documented vaccination may indicate inadequate immune response and warrants further investigation 4.

Clinical Manifestations

The clinical presentation is notoriously nonspecific, creating diagnostic challenges:

Primary Symptoms (in order of frequency):

• Fever: Present in 61-74% of cases 2, 3
• Cough: 72% of cases 2
• Loss of appetite and weight loss: 40% 2
• Night sweats and constitutional symptoms: Common but nonspecific 6, 7
• Gastrointestinal symptoms: Diarrhea and vomiting in 33% 2

Physical Examination Findings:

• Hepatomegaly: 82% of cases 2
• Splenomegaly: 54% 2
• Lymphadenopathy: 46% 2
• Pyrexia: 39% at presentation 2
• Respiratory findings: Rales in 61% of cases 3

Critical Complications:

Central nervous system involvement is the most significant prognostic factor:

• Occurs in 10-40% of miliary TB cases 1, 7
• Tuberculous meningitis was present in 19-30% of pediatric cases 2, 3
• Crucially, many children with CNS involvement have no neurological symptoms despite abnormal brain imaging 1—this means routine CNS evaluation should be considered even in asymptomatic patients

Other extrapulmonary manifestations include:

• Abdominal involvement: 15-30% 7
• Skeletal involvement: up to 17% 7
• Over 60% of patients have some form of extrapulmonary complication 7

Diagnostic Challenges:

Tuberculin skin test sensitivity is poor: Only 46.9% sensitive in miliary TB 1, with some series showing positive reactions in only 26% (6/23) of children at admission 3 and 68% (13/19) in another 6. This anergy is common due to the immunosuppressed state caused by disseminated disease 2.

Microbiological confirmation is difficult:

• Overall confirmation rate: 55.8% 1
• Culture positivity ranges from 21-33% 2, 3
• QuantiFERON Gold sensitivity: 72.4% 1

Radiographic findings are more reliable: 91% of cases show the classic miliary pattern on chest X-ray 2, though this may be absent early in disease.

Prognosis and Mortality

Overall mortality: 14-30.6% across multiple studies 1, 2, 3

Key Prognostic Factors:

1. CNS involvement is the single most significant risk factor for mortality 2—mortality reaches 31.9% when meningitis is present 1

2. Era of treatment: Mortality was significantly higher (41.5%) in publications before 1995 compared to more recent series 1, reflecting improved diagnostics and treatment protocols

3. Age: Infants under 1 year are at highest risk for both developing miliary TB and having worse outcomes 2, 3

4. Disease severity at presentation: Far advanced disease at diagnosis carries poor prognosis 6

5. Nutritional status: Most patients are malnourished at presentation, which contributes to poor outcomes 2

Favorable Prognostic Indicators:

• Outcome is generally excellent when CNS involvement is absent and diagnosis is made early 3, 6
• Children without meningitis who receive timely treatment show rapid clinical improvement 4
• Standard 6-month therapy (HRZE-HR regimen) is effective for isolated pulmonary miliary TB 7

Clinical Approach

Given the high mortality and diagnostic challenges:

1. Maintain high index of suspicion in any child under 5 years with prolonged fever (>2 weeks), constitutional symptoms, and hepatosplenomegaly, especially with known TB exposure 2, 6

2. Do not rely on tuberculin testing alone—negative tests occur in over 50% of cases due to anergy 1, 3

3. Obtain chest imaging early—the miliary pattern is present in 91% of cases and may be the most reliable diagnostic finding 2

4. Evaluate for CNS involvement routinely, even without neurological symptoms, as many children with CNS disease are asymptomatic initially 1. Whether both lumbar puncture and brain imaging should be done routinely versus a stepwise approach remains unclear and requires clinical judgment 1.

5. Pursue aggressive microbiological diagnosis with multiple specimens (gastric aspirates, induced sputum, nasopharyngeal swabs with molecular testing) 6, 4, though treatment should not be delayed for confirmation given the high mortality risk

6. Extended treatment duration: 9-12 months plus adjunctive dexamethasone is required for CNS complications, compared to standard 6-month therapy for isolated pulmonary disease 7